Published Research

 

IAVI routinely supports original research in a wide variety of fields including scientific and clinical research as well as policy analysis and sociological study in support of AIDS vaccine development. Much of this work is conducted in collaboration with our partners worldwide.  This section highlights the articles written by IAVI staff and/or IAVI-sponsored research that have been published in peer-reviewed and other highly-regarded journals.

Recent Articles Authored by IAVI Staff

Virology: Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies.

Published: 2012

Recent discovery of several potent and broadly neutralizing monoclonal antibodies (MAbs) (such as PG9 and PG16) to HIV-1 provided clues on newer vaccine targets. In the present study, we found an env clone obtained from a slow progressor showing significan...

Journal of acquired immune deficiency syndromes: Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth.

Published: 2012

Abstract OBJECTIVE: To identify and describe populations at risk for HIV in three clinical research centers (CRCs) in Kenya and South Africa. Design: Prospective cohort study METHODS: Volunteers reporting recent sexual activity, multiple partners, transac...

Journal of biological chemistry: Biochemically defined HIV-1 Env variant immunogens display differential binding and neutralizing specificities to the CD4 binding site

Published: 2012

HIV-1 gp120 binds the primary receptor, CD4. Recently, a plethora of broadly neutralizing antibodies to the gp120 CD4 binding site (CD4bs), validate this region to target for immunogen design. Here, we asked if modified HIV-1 envelope glycoproteins (Env) d...

Vaccine: HIV vaccine development: Challenges and opportunities towards a solution of the HIV vaccine-neutralizing antibody problem.

Published: 2012

Recent advances in HIV vaccine development have created a renaissance in the search for a safe and effective HIV vaccine. These advances include the first demonstration in human clinical trials of a vaccine candidate that provided modest levels of protecti...

Proceedings of the National Academy of Sciences: Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque

Published: 2011

It is widely believed that the induction of a broadly neutralizing antibody (bNAb) response will be a critical component of a successful vaccine against HIV. A significant fraction of HIV-infected individuals mount bNAb responses, providing support for the...


Search Articles

 

 View all IAVI-authored articles




charity navigator